Giv­ing it a GO: Gi­ant Roche se­lects a tiny play­er at Lab­Cen­tral for its next can­cer R&D part­ner

Roche has just inked its lat­est deal in the on­col­o­gy field. And while the terms may be mod­est by to­day’s in­dus­try stan­dards, it’s still a ma­jor league en­dorse­ment for the tiny biotech which scored the con­nec­tion.

Lit­tle GO Ther­a­peu­tics, which has a staff of 5 work­ing in shared lab space at Lab­Cen­tral in Cam­bridge, MA, is get­ting $9 mil­lion up­front for the pact, which spot­lights their work on O-linked gly­co­sy­la­tion. There’s an­oth­er $186 mil­lion in mile­stones, com­plet­ing a pack­age that has been in the works for some time, as GO worked with Roche’s pRED group based in Basel.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.